Sangamo Therapeutics (SGMOQ) Total Non-Current Liabilities (2013 - 2025)

Sangamo Therapeutics' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $73.4 million for Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities fell 5.77% year-over-year to $73.4 million in Q4 2025; TTM through Dec 2025 was $73.4 million, a 5.77% decrease from a year earlier, with the FY2025 full-year figure at $73.4 million, down 5.77% from the prior year.
• Total Non-Current Liabilities retreated to $73.4 million in Q4 2025 per SGMOQ's latest filing, from $81.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $400.4 million in Q1 2021 and bottomed at $68.1 million in Q2 2024.
• The 5-year median for Total Non-Current Liabilities is $86.8 million (2023), against an average of $180.6 million.
• Across the five-year window, Total Non-Current Liabilities surged 117.66% in 2021 and tumbled 70.56% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $345.4 million in 2021, then slipped by 22.88% to $266.3 million in 2022, then sank by 69.5% to $81.2 million in 2023, then decreased by 4.08% to $77.9 million in 2024, then dropped by 5.77% to $73.4 million in 2025.
• Per Business Quant, the three latest SGMOQ Total Non-Current Liabilities figures stand at $73.4 million (Q4 2025), $81.4 million (Q3 2025), and $77.0 million (Q2 2025).